Form 4: Director Carl Dambkowski Sells $6.2M in Oruka Stock

Oruka Therapeutics Director Carl Dambkowski executed a series of option exercises and stock sales totaling 105,000 shares under a pre-arranged trading plan.

Summary

• Director Carl Dambkowski exercised options to acquire 62,260 shares of common stock at exercise prices ranging from $6.84 to $11.77.
• Following the exercises, the reporting person sold a total of 105,000 shares in multiple transactions on May 21, 2026.
• The sales were executed at weighted average prices ranging from $58.43 to $59.97 per share.
• Total gross proceeds from the sales amounted to approximately $6,201,000.
• The transactions were conducted under a Rule 10b5-1 trading plan adopted on February 19, 2026.
• After these transactions, Carl Dambkowski directly owns 73,743 shares of Oruka Therapeutics.

Sentiment

Score: 4

Explanation: StockSavvy.ai views this as slightly negative due to the high volume of selling relative to the director's total position, though the use of a 10b5-1 plan provides a level of governance comfort.

Positives

• Transactions were performed under a Rule 10b5-1 trading plan, which helps mitigate concerns regarding timing and potential insider trading.
• The director maintains a significant remaining stake of 73,743 shares in the company.
• The exercise of options at prices as low as $6.84 demonstrates significant value creation compared to the current market price near $60.00.

Negatives

• The sale of 105,000 shares represents a substantial reduction in the director's total potential holding.
• Large-scale insider selling can sometimes be perceived by the market as a lack of confidence in near-term price appreciation.
• The volume of shares sold in a single day (105,000) could create temporary downward pressure on the stock price.

Risks

• Market volatility may occur if investors interpret the large sale as a signal of a local peak in valuation.
• The reliance on 10b5-1 plans does not fully eliminate the risk of negative investor sentiment following large divestments.

Future Outlook

The reporting person still holds 73,743 shares directly and retains various unvested stock options, suggesting continued alignment with the company's long-term performance despite the recent liquidity event.

Management Comments

• The reporting person undertakes to provide full information regarding the number of shares sold at each separate price within the ranges set forth upon request.

Industry Context

StockSavvy.ai notes that in the biotechnology sector, it is common for directors and executives to utilize 10b5-1 plans to diversify their portfolios, especially after significant stock price appreciation or clinical milestones.

Comparison to Industry Standards

• The use of a 10b5-1 plan is a standard best practice for corporate governance among NASDAQ-listed biotech firms like Moderna or Amgen.
• The sale volume is relatively high for a single director but not unusual for companies with high stock price volatility.
• The exercise-and-sell strategy is a frequent method for insiders to realize gains on expiring or vesting equity compensation.

Related Party Transactions

• The reporting person exercised options and sold shares of the issuer, which are considered related party transactions under Section 16 of the Securities Exchange Act.

Stakeholder Impact

• Shareholders may experience short-term price volatility due to the increased supply of shares in the market.
• The transaction provides liquidity to a key director, which is a standard part of executive compensation.

Next Steps

• Monitor for additional Form 4 filings from other insiders to determine if this is a coordinated divestment.
• Watch for upcoming clinical data or corporate updates that may have triggered the timing of the 10b5-1 plan sales.

Key Dates

Recommendation

While the insider selling is substantial, it was planned months in advance via a 10b5-1 plan. Investors should maintain their positions while monitoring the company's fundamental progress and clinical pipeline.

Keywords

Oruka Therapeutics, ORKA, Insider Selling, Form 4, Stock Options, Rule 10b5-1, Carl Dambkowski, Biotechnology